

Vanna Chiarion Sileni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2008230/publications.pdf>

Version: 2024-02-01

232
papers

47,867
citations

13332

70
h-index

2018

212
g-index

238
all docs

238
docs citations

238
times ranked

36453
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 127-137.	0.8	446
2	Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. <i>Journal of Translational Medicine</i> , 2022, 20, 159.	1.8	12
3	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2022, 399, 1718-1729.	6.3	236
4	Altitude Effect on Cutaneous Melanoma Epidemiology in the Veneto Region (Northern Italy): A Pilot Study. <i>Life</i> , 2022, 12, 745.	1.1	0
5	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021, 124, 574-580.	2.9	27
6	No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. <i>Cancers</i> , 2021, 13, 475.	1.7	20
7	Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program. <i>Journal of Translational Medicine</i> , 2021, 19, 70.	1.8	5
8	Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 627527.	1.3	4
9	Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study. <i>ESMO Open</i> , 2021, 6, 100064.	2.0	21
10	The immune cell landscape of metastatic uveal melanoma correlates with overall survival. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 154.	3.5	19
11	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021, 22, 655-664.	5.1	37
12	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021, 22, 643-654.	5.1	224
13	Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 4737-4745.	3.2	35
14	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). <i>European Journal of Cancer</i> , 2021, 152, 116-128.	1.3	7
15	Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. <i>International Journal of Cancer</i> , 2021, 149, 1926-1934.	2.3	8
16	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12
17	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2021, 158, 156-168.	1.3	19
18	Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy). <i>Targeted Oncology</i> , 2021, 16, 789-799.	1.7	5

#	ARTICLE	IF	CITATIONS
19	Merkel Cell Carcinoma: Evaluation of the Clinico-Pathological Characteristics, Treatment Strategies and Prognostic Factors in a Monocentric Retrospective Series (n=143). <i>Frontiers in Oncology</i> , 2021, 11, 737842.	1.3	6
20	Systemic treatments for metastatic cutaneous melanoma. <i>The Cochrane Library</i> , 2020, 2020, CD011123.	1.5	136
21	Cholecystectomy during esophagectomy is safe but unnecessary. <i>Acta Chirurgica Belgica</i> , 2020, 120, 35-41.	0.2	1
22	Cost-effectiveness of a melanoma screening programme using whole disease modelling. <i>Journal of Medical Screening</i> , 2020, 27, 157-167.	1.1	2
23	Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3937-3946.	0.8	119
24	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1435-1448.	0.6	132
25	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. <i>Frontiers in Oncology</i> , 2020, 10, 1652.	1.3	10
26	LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno) Tj ETQq0.0.0 rgBT /Overlock 1	0.6	22
27	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1449-1461.	0.6	69
28	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020, 383, 1139-1148.	13.9	256
29	Adjuvant nivolumab versus ipilimumab in resected stage IIIbâ€“C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1465-1477.	5.1	330
30	1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238. <i>Annals of Oncology</i> , 2020, 31, S731-S732.	0.6	7
31	1081MO Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial. <i>Annals of Oncology</i> , 2020, 31, S734.	0.6	5
32	1100P Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanoma. <i>Annals of Oncology</i> , 2020, 31, S743-S744.	0.6	0
33	Identification of host variants associated with overall survival of esophageal cancer patients receiving platinum-based therapy. <i>Pharmacogenomics</i> , 2020, 21, 393-402.	0.6	0
34	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. , 2020, 8, e000391.		39
35	A Therapeutic and Diagnostic Multidisciplinary Pathway for Merkel Cell Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 529.	1.3	8
36	Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 358-372.	5.1	94

#	ARTICLE	IF	CITATIONS
37	Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study. <i>BMC Cancer</i> , 2019, 19, 772.	1.1	24
38	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 119, 1-10.	1.3	132
39	PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus. <i>Cancer Medicine</i> , 2019, 8, 6036-6048.	1.3	23
40	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. <i>European Journal of Cancer</i> , 2019, 119, 97-106.	1.3	75
41	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 121, 144-153.	1.3	27
42	The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. , 2019, 7, 308.		51
43	Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach. <i>Journal of Translational Medicine</i> , 2019, 17, 289.	1.8	24
44	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 119, 168-178.	1.3	61
45	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 1535-1546.	13.9	2,484
46	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 626-636.	13.9	909
47	Squamous cell carcinoma antigen 1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity. <i>Cancer Science</i> , 2019, 110, 1552-1563.	1.7	21
48	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 701-710.	5.1	50
49	Reply to E. Hindi and K.R. Hess. <i>Journal of Clinical Oncology</i> , 2019, 37, 1356-1358.	0.8	1
50	Effectiveness of dabrafenib in the treatment of patients with BRAF V600E-mutated metastatic melanoma in a Named Patient Program. <i>Melanoma Research</i> , 2019, 29, 527-532.	0.6	6
51	Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells. <i>Melanoma Research</i> , 2019, 29, 89-94.	0.6	4
52	An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. <i>European Journal of Cancer</i> , 2019, 107, 175-185.	1.3	13
53	Prognostic impact of regression in patients with primary cutaneous melanoma >1mm in thickness. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 99-105.e5.	0.6	19
54	Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	3.4	295

#	ARTICLE	IF	CITATIONS
55	Optimization of resources by drug management: A multicentred web-administered study on the use of ipilimumab in Italy. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 787-792.	0.5	6
56	Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with <i>BRAF</i> V600 mutant unresectable or metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 9507-9507.	0.8	8
57	Adjuvant vemurafenib in resected, <i>BRAF</i> V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 510-520.	5.1	183
58	<i>BRAF</i> Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1332-1340.	1.9	21
59	Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. <i>Journal of Translational Medicine</i> , 2018, 16, 94.	1.8	132
60	Time to diagnosis in esophageal cancer: a cohort study. <i>Acta Oncologica</i> , 2018, 57, 1179-1184.	0.8	14
61	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with <i>BRAF</i> -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 603-615.	5.1	751
62	Esophageal Cancer Clinical Presentation. <i>Annals of Surgery</i> , 2018, 267, 99-104.	2.1	25
63	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600 Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3441-3449.	0.8	226
64	Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. <i>Annals of Oncology</i> , 2018, 29, viii445.	0.6	2
65	Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma. <i>Scientifica</i> , 2018, 2018, 1-7.	0.6	14
66	Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients. <i>Cancers</i> , 2018, 10, 350.	1.7	17
67	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1480-1492.	5.1	1,089
68	Overall survival in patients with <i>BRAF</i> -mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1315-1327.	5.1	469
69	Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines. <i>Acta Dermato-Venereologica</i> , 2018, 98, 218-224.	0.6	24
70	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238). <i>Journal of Clinical Oncology</i> , 2018, 36, 9502-9502.	0.8	52
71	Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in <i>BRAF</i> -mutant melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 9504-9504.	0.8	23
72	Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III <i>BRAF</i> -mutant melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 9590-9590.	0.8	9

#	ARTICLE	IF	CITATIONS
73	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 393-403.	5.1	91
74	Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis. <i>Cancer Treatment Reviews</i> , 2017, 54, 34-42.	3.4	46
75	Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study. <i>Journal of Chemotherapy</i> , 2017, 29, 245-251.	0.7	6
76	Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. <i>European Journal of Cancer</i> , 2017, 79, 176-184.	1.3	31
77	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , 2017, 28, 1631-1639.	0.6	549
78	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017, 82, 45-55.	1.3	160
79	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 863-873.	5.1	561
80	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 611-622.	5.1	428
81	Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1813-1823.	13.9	1,192
82	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.	13.9	1,752
83	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356.	13.9	3,589
84	CASE STUDY ON AN IPILIMUMAB COST-CONTAINMENT STRATEGY IN AN ITALIAN HOSPITAL. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 199-205.	0.2	5
85	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017, 82, 80-91.	1.3	76
86	Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. <i>Clinical Cancer Research</i> , 2017, 23, 1929-1936.	3.2	290
87	Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 264-273.e2.	0.6	41
88	Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma. <i>Annals of Oncology</i> , 2017, 28, v442.	0.6	2
89	A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience. <i>European Journal of Dermatology</i> , 2017, 27, 482-486.	0.3	10
90	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 3807-3814.	0.8	364

#	ARTICLE	IF	CITATIONS
91	Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067). Cancer Research, 2017, 77, CT075-CT075.	0.4	34
92	Squamous cell carcinoma antigen (SCCA) is up-regulated during Barrett's carcinogenesis and predicts esophageal adenocarcinoma resistance to neoadjuvant chemotherapy. Oncotarget, 2017, 8, 24372-24379.	0.8	10
93	A germline predictive signature of response to platinum chemotherapy in esophageal cancer. Translational Research, 2016, 171, 29-37.e1.	2.2	16
94	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. New England Journal of Medicine, 2016, 375, 1845-1855.	13.9	1,140
95	Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. Oncoimmunology, 2016, 5, e1249559.	2.1	51
96	Genetic risk of subsequent esophageal cancer in lymphoma and breast cancer long-term survival patients: a pilot study. Pharmacogenomics Journal, 2016, 16, 266-271.	0.9	4
97	Interferon alpha for the adjuvant treatment of cutaneous melanoma. The Cochrane Library, 2015, 2015, CD008955.	1.5	110
98	Development and External Validation of a Prognostic Nomogram for Metastatic Uveal Melanoma. PLoS ONE, 2015, 10, e0120181.	1.1	33
99	Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases. Melanoma Research, 2015, 25, 75-79.	0.6	27
100	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 2015, 373, 23-34.	13.9	6,773
101	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet, The, 2015, 386, 444-451.	6.3	1,175
102	Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib. Radiology and Oncology, 2015, 49, 71-74.	0.6	28
103	Nivolumab in Previously Untreated Melanoma without BRAF Mutation. New England Journal of Medicine, 2015, 372, 320-330.	13.9	4,795
104	Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab. European Journal of Cancer, 2015, 51, 2086-2094.	1.3	45
105	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. European Journal of Cancer, 2015, 51, 833-840.	1.3	71
106	A retrospective analysis of 141 patients with liver metastases from uveal melanoma. Melanoma Research, 2015, 25, 164-168.	0.6	34
107	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC Tj ETQq1 1 0,784314 rgrBT /Overall	5.1	1,093
108	Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. Journal of Clinical Oncology, 2015, 33, 1191-1196.	0.8	445

#	ARTICLE	IF	CITATIONS
109	12th National Congress of the Italian Association of Nuclear Medicine and Molecular Imaging (AIMN) Rimini (Italy), April 16-19, 2015. Clinical and Translational Imaging, 2015, 3, 1-144.	1.1	4
110	Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncology, The, 2015, 16, 1389-1398.	5.1	206
111	Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. Future Oncology, 2015, 11, 1355-1362.	1.1	6
112	Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. New England Journal of Medicine, 2015, 372, 30-39.	13.9	2,240
113	Genetic Features of Metachronous Esophageal Cancer Developed in Hodgkin's Lymphoma or Breast Cancer Long-Term Survivors: An Exploratory Study. PLoS ONE, 2015, 10, e0117070.	1.1	8
114	ecancermedalscience. Ecanermedalscience, 2014, 8, 440.	0.6	1
115	Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program. Cancer Investigation, 2014, 32, 144-149.	0.6	90
116	Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. British Journal of Cancer, 2014, 110, 1721-1726.	2.9	53
117	Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon. Journal of Chemotherapy, 2014, 26, 193-201.	0.7	17
118	Systemic treatments for metastatic cutaneous melanoma. The Cochrane Library, 2014, , .	1.5	12
119	18F-fluorodeoxyglucose PET/computed tomography and risk stratification after neoadjuvant treatment in esophageal cancer patients. Nuclear Medicine Communications, 2014, 35, 160-168.	0.5	5
120	Neoadjuvant treatment with dabrafenib of unresectable localizations from occult melanoma. Melanoma Research, 2014, 24, 413-414.	0.6	16
121	Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. Journal of Neuro-Oncology, 2014, 118, 109-116.	1.4	103
122	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. New England Journal of Medicine, 2014, 371, 1877-1888.	13.9	1,572
123	Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. Journal of Experimental and Clinical Cancer Research, 2014, 33, 30.	3.5	97
124	Clinical experience with ipilimumab 3Âmg/kg: real-world efficacy and safety data from an expanded access programme cohort. Journal of Translational Medicine, 2014, 12, 116.	1.8	149
125	Discrepant alterations in main candidate genes among multiple primary melanomas. Journal of Translational Medicine, 2014, 12, 117.	1.8	24
126	Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Annals of Oncology, 2014, 25, 1428-1436.	0.6	45

#	ARTICLE	IF	CITATIONS
127	Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. <i>Lancet Oncology</i> , The, 2014, 15, 436-444.	5.1	242
128	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. <i>European Journal of Cancer</i> , 2014, 50, 121-127.	1.3	149
129	Clinical electrochemotherapy for advanced superficial melanoma. , 2014, , 35-53.		2
130	COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF^{V600E/K}mutation-positive cutaneous melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 9011-9011.	0.8	40
131	Complete Clinical Response After Neoadjuvant Chemoradiotherapy for Squamous Cell Cancer of the Thoracic Oesophagus: Is Surgery Always Necessary?. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 1375-1381.	0.9	77
132	Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 897-908.	2.0	31
133	Paraneoplastic cerebellar degeneration with anti-Yo antibodies associated with metastatic uveal melanoma. <i>Journal of the Neurological Sciences</i> , 2013, 335, 210-212.	0.3	12
134	Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2413-2420.	0.8	188
135	Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 1211-1218.	0.8	182
136	Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. <i>Annals of Oncology</i> , 2013, 24, 2911-2915.	0.6	119
137	Follow-Up of Melanoma: A Survey of Italian Hospitals. <i>Dermatology</i> , 2013, 226, 32-38.	0.9	9
138	Surgical Management of Suspicious Melanocytic Lesions in Italy. <i>Dermatology</i> , 2013, 226, 18-21.	0.9	1
139	Management of Small and Intermediate Congenital Nevi: A Nationwide Survey in Italy. <i>Dermatology</i> , 2013, 226, 7-12.	0.9	5
140	Diagnostic and Therapeutic Approaches in Italian Hospitals: Adjuvant and Metastatic Therapy in Melanoma. <i>Dermatology</i> , 2013, 226, 22-27.	0.9	4
141	Impact of Mole Mapping in the Italian Health System. <i>Dermatology</i> , 2013, 226, 13-17.	0.9	2
142	Clinical experience with ipilimumab 10Âmg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 82.	3.5	23
143	Surgical Treatment of Melanoma: A Survey of Italian Hospitals. <i>Dermatology</i> , 2013, 226, 28-31.	0.9	21
144	Diagnostic Services for Melanoma in Italy. <i>Dermatology</i> , 2013, 226, 3-6.	0.9	2

#	ARTICLE	IF	CITATIONS
145	Melanoma Task Force (META) Project in Italy: Methodology. <i>Dermatology</i> , 2013, 226, 1-2.	0.9	18
146	An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9013-9013.	0.8	68
147	Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9070-9070.	0.8	9
148	Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon- γ . <i>Melanoma Research</i> , 2012, 22, 284-285.	0.6	4
149	Overdose of Vinblastine in place of Vinorelbine during ICEV chemotherapy. <i>Immunopharmacology and Immunotoxicology</i> , 2012, 34, 879-880.	1.1	8
150	Positron emission tomography/computed tomography and esophageal cancer in the clinical practice: How does it affect the prognosis?. <i>Journal of Cancer Research and Therapeutics</i> , 2012, 8, 619.	0.3	14
151	Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class II Modified Peptides. <i>Clinical Cancer Research</i> , 2012, 18, 6485-6496.	3.2	61
152	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2012, 380, 358-365.	6.3	2,691
153	The cost of unresectable stage III or stage IV melanoma in Italy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 91.	3.5	25
154	Safety and Efficacy of Ipilimumab 10 Mg/Kg Among Patients with Advanced Melanoma from Italy Enrolled in a European Compassionate Use Program. <i>Annals of Oncology</i> , 2012, 23, ix373-ix374.	0.6	0
155	Electrochemotherapy for disseminated superficial metastases from malignant melanoma. <i>British Journal of Surgery</i> , 2012, 99, 821-830.	0.1	89
156	A Case of Squamous Cell Carcinoma of the Scalp After Several Synthetic Hair Grafts. <i>Aesthetic Plastic Surgery</i> , 2012, 36, 649-652.	0.5	6
157	Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 41-48.	2.0	118
158	Efficacy and Safety of Ipilimumab in Patients with Pretreated, Ocular Melanoma: Experience from Italian Clinics Participating in the European Expanded Access Programme (EAP). <i>Annals of Oncology</i> , 2012, 23, ix369-ix370.	0.6	1
159	Contribution of susceptibility gene variants to melanoma risk in families from the Veneto region of Italy. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 728-730.	1.5	12
160	A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. <i>British Journal of Cancer</i> , 2011, 104, 427-432.	2.9	42
161	Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. <i>British Journal of Cancer</i> , 2011, 104, 1816-1821.	2.9	53
162	Interval Between Neoadjuvant Chemoradiotherapy and Surgery for Squamous Cell Carcinoma of the Thoracic Esophagus. <i>Annals of Surgery</i> , 2010, 252, 788-796.	2.1	66

#	ARTICLE	IF	CITATIONS
163	Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. <i>Annals of Oncology</i> , 2010, 21, 1712-1717.	0.6	468
164	Trends in Management and Prognosis for Esophageal Cancer Surgery. <i>Archives of Surgery</i> , 2009, 144, 247.	2.3	102
165	Small molecules and targeted therapies in distant metastatic disease. <i>Annals of Oncology</i> , 2009, 20, vi35-vi40.	0.6	75
166	Surgery and radiotherapy in the treatment of cutaneous melanoma. <i>Annals of Oncology</i> , 2009, 20, vi22-vi29.	0.6	96
167	Functional impairment of p16INK4A due to CDKN2A p.Gly23Asp missense mutation. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2009, 671, 26-32.	0.4	14
168	Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1111-1119.	1.1	22
169	Anetoderma in cutaneous marginal-zone B-cell lymphoma. <i>Clinical and Experimental Dermatology</i> , 2009, 34, e945-e948.	0.6	5
170	Bleomycin-Based Electrochemotherapy: Clinical Outcome from a Single Institution's Experience with 52 Patients. <i>Annals of Surgical Oncology</i> , 2009, 16, 191-199.	0.7	256
171	IL4R α + Myeloid-Derived Suppressor Cell Expansion in Cancer Patients. <i>Journal of Immunology</i> , 2009, 182, 6562-6568.	0.4	287
172	9315 Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy. <i>European Journal of Cancer</i> , Supplement, 2009, 7, 581.	2.2	3
173	6565 The role of PET-TC in predicting the pCR in locally-advanced esophageal cancer (LAEC) after a preoperative CT-RT treatment: data from B152 trial. <i>European Journal of Cancer</i> , Supplement, 2009, 7, 380.	2.2	0
174	9307 Long-term survival in advanced melanoma patients treated with ipilimumab at 10 mg/kg: ongoing analyses from completed Phase II trials. <i>European Journal of Cancer</i> , Supplement, 2009, 7, 578.	2.2	5
175	Complete and lasting healing of bone melanoma metastasis after hyperthermic limb perfusion. <i>Melanoma Research</i> , 2009, 19, 193-194.	0.6	0
176	A multicenter phase II study of induction CT with FOLFOX-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC). <i>Journal of Clinical Oncology</i> , 2009, 27, 4546-4546.	0.8	2
177	TNF-Based Isolated Limb Perfusion Followed by Consolidation Biotherapy with Systemic Low-dose Interferon Alpha 2b in Patients with In-transit Melanoma Metastases: A Pilot Trial. <i>Annals of Surgical Oncology</i> , 2008, 15, 1218-1223.	0.7	17
178	Primary Subcutaneous B-cell Lymphoma: Case Report and Literature Review. <i>Acta Dermato-Venereologica</i> , 2008, 88, 151-154.	0.6	6
179	Reversible, PET-positive, Generalized Lymphadenopathy and Splenomegaly During High-dose Interferon- α -2b Adjuvant Therapy for Melanoma. <i>Journal of Immunotherapy</i> , 2008, 31, 675-678.	1.2	7
180	Expression of defined genes identified by pretreatment tumor profiling: Association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients (EORTC Tj ETQq0 0 0 rgBT / Overlock 10 Tf 50 57		

#	ARTICLE	IF	CITATIONS
181	Primary Mediastinal Large B-Cell Lymphoma: Results of Intensive Chemotherapy Regimens (MACOP-B/VACOP-B) Plus Involved Field Radiotherapy on 53 Patients. A Single Institution Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 823-829.	0.4	48
182	Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. <i>British Journal of Cancer</i> , 2007, 96, 432-438.	2.9	35
183	Results of esophagectomy for esophageal cancer in elderly patients: Age has little influence on outcome and survival. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007, 133, 1186-1192.	0.4	131
184	Effects of Neoadjuvant Therapy on Perioperative Morbidity in Elderly Patients Undergoing Esophagectomy for Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2007, 14, 3243-3250.	0.7	74
185	A gene expression signature associated with survival in metastatic melanoma. <i>Journal of Translational Medicine</i> , 2006, 4, 50.	1.8	93
186	Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma. <i>Melanoma Research</i> , 2006, 16, 317-323.	0.6	10
187	Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer. <i>British Journal of Cancer</i> , 2006, 94, 1550-1552.	2.9	4
188	Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI "Mel.A.) [ISRCTN75125874]. <i>BMC Cancer</i> , 2006, 6, 44.	1.1	22
189	Treatment of Chemotherapy-Induced Oral Mucositis with Light-Emitting Diode. <i>Photomedicine and Laser Surgery</i> , 2006, 24, 207-213.	2.1	53
190	Treatments of AIDS-related Kaposi's sarcoma. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 53, 253-265.	2.0	48
191	Stanford V Regimen plus Consolidative Radiotherapy Is an Effective Therapeutic Program for Bulky or Advanced-Stage Hodgkin's Disease. <i>Acta Haematologica</i> , 2004, 112, 141-147.	0.7	12
192	Randomized Phase III Trial of Neoadjuvant Chemotherapy in Head and Neck Cancer: 10-Year Follow-Up. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1714-1717.	3.0	167
193	Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. <i>International Journal of Cancer</i> , 2004, 111, 741-745.	2.3	53
194	Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 51, 171-189.	2.0	19
195	Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. <i>Lung Cancer</i> , 2004, 43, 83-91.	0.9	58
196	Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Inter-group. <i>Melanoma Research</i> , 2004, 14, 295-299.	0.6	16
197	Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial. <i>Journal of Translational Medicine</i> , 2003, 1, 13.	1.8	10
198	Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. <i>European Journal of Cancer</i> , 2003, 39, 1577-1585.	1.3	56

#	ARTICLE	IF	CITATIONS
199	Large and Dissimilar Repertoire of Melan-A/MART-1-Specific CTL in Metastatic Lesions and Blood of a Melanoma Patient. <i>Journal of Immunology</i> , 2002, 169, 4017-4024.	0.4	42
200	Cisplatin, Dacarbazine With or Without Subcutaneous Interleukin-2, and Interferon Alfa-2b in Advanced Melanoma Outpatients: Results From an Italian Multicenter Phase III Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 1600-1607.	0.8	80
201	Radiotherapy Alone in the Treatment of Clinical Stage I-IIA, Nonbulky, Hodgkin's Disease. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 149-152.	0.6	2
202	Cisplatin, Dacarbazine With or Without Subcutaneous Interleukin-2, and Interferon Alfa-2b in Advanced Melanoma Outpatients: Results From an Italian Multicenter Phase III Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 1600-1607.	0.8	111
203	Phase II trial of interferon- γ plus psolarene with ultraviolet light A in patients with cutaneous T-cell lymphoma. <i>Cancer</i> , 2002, 95, 569-575.	2.0	89
204	Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. <i>Melanoma Research</i> , 2001, 11, 189-196.	0.6	70
205	Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma. <i>Cancer</i> , 2001, 91, 2165-2174.	2.0	362
206	Elderly Ovarian Cancer: Treatment with Mitoxantrone + Carboplatin. <i>Gynecologic Oncology</i> , 2001, 80, 221-226.	0.6	8
207	VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. <i>Journal of Clinical Oncology</i> , 1998, 16, 2796-2802.	0.8	204
208	First-Line Chemotherapy Improves the Resection Rate and Long-Term Survival of Locally Advanced (T4) Tj ETQq0 0.0 rgBT /Overlock 10	2.1	62
209	Pre-operative chemoradiotherapy in non-small cell lung cancer stage III patients. feasibility, toxicity and long-term results of a phase II study. <i>European Journal of Cancer</i> , 1996, 32, 2064-2069.	1.3	18
210	Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease. <i>Annals of Oncology</i> , 1995, 6, 173-179.	0.6	3
211	Phase III Trial of Initial Chemotherapy in Stage III or IV Head and Neck Cancers: a Study by the Gruppo di Studio sui Tumori della Testa e del Collo. <i>Journal of the National Cancer Institute</i> , 1994, 86, 265-272.	3.0	395
212	Epirubicin, methotrexate and bleomycin in the management of recurrent squamous cell head and neck cancer. A GSTTC randomised phase II study. <i>European Journal of Cancer</i> , 1993, 29, 704-708.	1.3	6
213	A Pilot Study of Concomitant Radiation and Chemotherapy in Patients with Locally Advanced Head and Neck Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1993, 16, 264-267.	0.6	6
214	Secondary Leukemia following Treatment for Hodgkin's Disease. <i>Tumori</i> , 1993, 79, 103-107.	0.6	10
215	Late relapses in Hodgkin's disease: Outcome of patients relapsing more than twelve months after primary chemotherapy. <i>Annals of Oncology</i> , 1993, 4, 657-662.	0.6	15
216	A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1992, 3, 833-837.	0.6	33

#	ARTICLE	IF	CITATIONS
217	Extramedullary plasmacytoma: Clinical behaviour and response to treatment. <i>Annals of Oncology</i> , 1992, 3, 51-57.	0.6	73
218	Deflazacort and Fluoximesterone in Advanced, Pretreated Breast Cancer. <i>Tumori</i> , 1992, 78, 266-269.	0.6	1
219	Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 30, 221-225.	1.1	27
220	Second and third responses to the same induction regimen in relapsing patients with multiple myeloma. <i>Cancer</i> , 1991, 68, 975-980.	2.0	16
221	Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm. <i>Cancer</i> , 1990, 65, 2631-2634.	2.0	27
222	Leucovorin calcium enhancement of mucositis after continuous infusion fluorouracil and short infusion cisplatin.. <i>Journal of Clinical Oncology</i> , 1989, 7, 680-681.	0.8	4
223	Recombinant alpha-Interferon and vinblastine in metastatic renal cell carcinoma: Efficacy of low doses. <i>Journal of Surgical Oncology</i> , 1988, 4, 184-190.	1.4	18
224	Pepticchemio in pretreated patients with plasmacell neoplasms. <i>European Journal of Cancer & Clinical Oncology</i> , 1986, 22, 1053-1058.	0.9	8
225	Cisplatin plus Vindesine versus Cisplatin plus VP16 versus Doxorubicin plus Cytosin in Non-Small-Cell Carcinoma of the Lung. A Randomized Study. <i>Tumori</i> , 1986, 72, 417-425.	0.6	11
226	Lipid Bound Sialic Acid in Cancer Patients. <i>Tumori</i> , 1985, 71, 127-133.	0.6	10
227	Vindesine in Plasma Cell Tumors. <i>Tumori</i> , 1985, 71, 533-536.	0.6	2
228	Urinary Hydroxyproline in Multiple Myeloma: Correlation with Clinical Stages and Bone Disease. <i>Tumori</i> , 1984, 70, 249-253.	0.6	2
229	Cisplatin, bleomycin and methotrexate in the treatment of advanced oesophageal cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1984, 20, 743-747.	0.9	21
230	Treatment of multiple myeloma with M-2 protocol and without maintenance therapy. <i>European Journal of Cancer & Clinical Oncology</i> , 1983, 19, 1345-1351.	0.9	29
231	Cis-Dichlorodiammineplatinum (II), VP 16-213, and Prednisone (Dvp Regimen) in the Treatment of Pretreated Advanced Malignant Lymphomas. <i>Tumori</i> , 1982, 68, 515-518.	0.6	2
232	Serum Copper Level in Non-Hodgkin's Lymphomas. <i>Tumori</i> , 1982, 68, 57-62.	0.6	3